AADAC Polyclonal Antibody

Sizes: 60μL, 120μL, 200μL

Catalogue Numbers: E-AB-10690-60, E-AB-10690-120, E-AB-10690-200

Citations, Manuals and MSDS Available upon request.

Abbreviation: AADAC

Target Synonym: AAAD; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC

Research Areas: Metabolism, Signal Transduction

Conjugation: Unconjugated

Host: Rabbit

Species Reactivity: Human

Application: WB, IHC, ELISA

Isotype: IgG

Clonality: Polyclonal

UNIProt ID: P22760

Background: Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

Concentration: 0.2 mg/mL

Immunogen: Recombinant protein of human AADAC

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification Method: Affinity purification

Dilution: WB 1:500-1:2000, IHC 1:50-1:100

Calculated MW: 46kDa

Storage: -20°C/One year. Avoid freeze / thaw cycles.

Shipping: Ice bag

Research Use Only